STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Ph 2 Sarcoma Trial of STC‑15
Jerry McMahon, Chief Executive Officer of STORM Therapeutics, said: “Advancing our first‑in‑class METTL3 inhibitor, STC-15, into Phase 2 clinical development marks a pivotal breakthrough in tackling cancers characterized by aberrant cell differentiation. This milestone highlights our scientific innovation and the potential to create new therapeutic options for patients with substantial unmet needs. We are grateful for the steadfast support from our investors and are encouraged by the robust durability and activity demonstrated with STC-15 in Phase 1 studies. As we begin our Phase 2 trial, our focus remains on addressing critical unmet needs in sarcoma for the benefit of patients.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000